Acutus developed mapping technology to try to reduce the rate of atrial fibrillation recurrence after patients undergo ablation. The company pitched its non-contact approach to mapping as a better fit for atrial fibrillation and other complex or unstable arrhythmias, but has struggled to translate its belief in the technology into commercial success.
Medtronic acquired Acutus’ left-heart access transseptal crossing business in 2022, paying $50 million upfront and an additional $20 million before the end of the year. The agreement made Medtronic the exclusive distributor of the devices but Acutus remained the manufacturer.
